Privium Fund Management B.V. Buys 22,500 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Privium Fund Management B.V. boosted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 22.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 121,000 shares of the company’s stock after buying an additional 22,500 shares during the period. Privium Fund Management B.V.’s holdings in 4D Molecular Therapeutics were worth $674,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of FDMT. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of 4D Molecular Therapeutics during the third quarter valued at about $295,000. Intech Investment Management LLC purchased a new position in 4D Molecular Therapeutics during the 3rd quarter valued at approximately $268,000. Algert Global LLC increased its stake in 4D Molecular Therapeutics by 342.7% in the 3rd quarter. Algert Global LLC now owns 73,436 shares of the company’s stock worth $794,000 after acquiring an additional 56,848 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth approximately $912,000. Finally, Braidwell LP boosted its position in shares of 4D Molecular Therapeutics by 231.7% during the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock valued at $13,247,000 after acquiring an additional 855,990 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

FDMT has been the topic of several research reports. Bank of America reduced their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Chardan Capital decreased their target price on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, March 7th. Royal Bank of Canada lowered their price objective on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Finally, BMO Capital Markets downgraded 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $40.00 to $15.00 in a research report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $30.63.

4D Molecular Therapeutics Stock Down 8.6 %

Shares of FDMT stock opened at $3.82 on Wednesday. The company’s 50 day moving average is $4.81 and its 200 day moving average is $7.62. The firm has a market cap of $176.87 million, a price-to-earnings ratio of -1.34 and a beta of 2.83. 4D Molecular Therapeutics, Inc. has a 52-week low of $3.73 and a 52-week high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). Analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.